Journal
EXPERT REVIEW OF RESPIRATORY MEDICINE
Volume 10, Issue 7, Pages 799-811Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/17476348.2016.1190646
Keywords
-
Categories
Funding
- Medtronic
- Novo Nordisk
- Abbott
Ask authors/readers for more resources
Introduction: Cystic fibrosis-related diabetes (CFRD) is the end-point of a spectrum of glucose abnormalities in cystic fibrosis that begins with early insulin deficiency and ultimately results in accelerated nutritional decline and loss of lung function. Current diagnostic and management regimens are unable to entirely reverse this clinical decline. Areas covered: This review summarises the current understanding of the pathophysiology of CFRD, the issues associated with using oral glucose tolerance tests in CF and the challenges faced in making the diagnosis of CFRD. Medline database searches were conducted using search terms Cystic Fibrosis Related Diabetes, Cystic Fibrosis AND glucose, Cystic Fibrosis AND insulin, Cystic Fibrosis AND Diabetes. Additionally, reference lists were studied. Expert commentary: Increasing evidence points to early glucose abnormalities being clinically relevant in cystic fibrosis and as such novel diagnostic methods such as continuous glucose monitoring or 30 minute sampled oral glucose tolerance test (OGTT)may play a key role in the future in the screening and diagnosis of early glucose abnormalities in CF.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available